mAbs

mAbs is a peer-reviewed multidisciplinary journal published by Taylor & Francis and affiliated with The Antibody Society, established in 2009 and dedicated to the art and science of antibody research and development, with a 2025 Journal Impact Factor of 7.9 and a first-quartile rank of 25 among 191 research and experimental medicine journals《单克隆抗体》（mAbs）是（Taylor & Francis）出版的同行评审多学科期刊，与（The Antibody Society）相关联，2009 年创刊，专注于抗体研究与开发的技术与科学，2025 年影响因子为 7.9，在 191 种研究与实验医学类期刊中列第 25 位，居第一四分位。

Scope

• Antibody engineering and selection, including display technologies, affinity maturation and format design, are central topics抗体工程与筛选（含展示技术、亲和力成熟与形式设计）是核心主题。
• Targets relevant to cancer, immune-mediated disorders and other diseases are covered from discovery through validation覆盖肿瘤、免疫介导疾病及其他疾病的靶点，从发现到验证全过程。
• Non-clinical studies such as mechanism-of-action work and safety and efficacy studies in animals are within scope作用机制研究以及动物体内的安全性与有效性等临床前研究属于收稿范围。
• Manufacturing, analytical characterization and quality control of antibody therapeutics form a substantial part of the journal抗体药物的生产制造、分析表征与质量控制占该刊相当篇幅。
• Clinical studies and regulatory review of antibody therapeutics are published, including submissions and approval summaries刊载抗体药物的临床研究与监管审评内容，包括申报资料与批准综述。
• Post-approval topics such as pricing, reimbursement and markets, and patents and intellectual property, are explicitly listed定价、报销与市场等上市后议题，以及专利与知识产权，均被明确列入。
• Emerging markets for antibody therapeutics, including China and India, and the wider policy and investment context of the field are also addressed还涉及包括中国与印度在内的抗体药物新兴市场，以及该领域更广泛的产业政策与投资背景。

History

• mAbs was established in 2009 and was originally published by Landes Bioscience in Austin, Texas, which explains the journal's JCR abbreviation MABS-AUSTIN该刊 2009 年创刊，最初由位于得克萨斯州奥斯汀的（Landes Bioscience）出版，这也是其 JCR 缩写（MABS-AUSTIN）的由来。
• It is now published by Taylor & Francis and serves as the journal of The Antibody Society, giving it a direct link to the antibody therapeutics community现由（Taylor & Francis）出版，并作为（The Antibody Society）的期刊，与抗体药物社群保持直接联系。
• The journal appears six times a year and publishes all content open access under Creative Commons licences, with an article processing charge of 2,915 pounds sterling该刊每年出版六期，全部内容以（Creative Commons）许可开放获取，文章处理费为 2,915 英镑。
• Its Journal Impact Factor rose from 5.857 in 2021 and 6.44 in 2022 to 7.3 in 2024 and 7.9 in 2025, alongside a CiteScore of 11.9其影响因子由 2021 年的 5.857、2022 年的 6.44 升至 2024 年的 7.3 与 2025 年的 7.9，CiteScore 为 11.9。
• It holds the DOAJ Seal and reports an average of eight weeks from submission to publication, with roughly 130 articles published in 2025该刊持有（DOAJ Seal），公布从投稿到发表平均约 8 周，2025 年发表约 130 篇论文。

Editors

• The Editor-in-Chief is Janice M. Reichert, who has led the journal since its founding and is associated with The Antibody Society in Boston现任主编为 Janice M. Reichert，自创刊起主持该刊，任职于波士顿的（The Antibody Society）。
• All submitted manuscripts receive an initial evaluation by editorial staff, and those found suitable are sent to independent, anonymous expert referees所有投稿先由编辑部初评，合适的稿件再送交独立的匿名专家评审。
• The editorial board spans antibody discovery, process development, clinical development and regulatory affairs, matching the journal's translational remit编委覆盖抗体发现、工艺开发、临床开发与法规事务，与刊物的转化定位相匹配。
• The journal's statistical reporting of the therapeutic antibody pipeline, compiled with The Antibody Society, is widely cited by industry and regulators该刊与（The Antibody Society）合作整理的治疗性抗体管线统计报告，被产业界与监管机构广泛引用。
• Content is hosted on the Taylor & Francis platform, with articles indexed in MEDLINE, PubMed, the Science Citation Index Expanded and Scopus内容托管于（Taylor & Francis）平台，文章被（MEDLINE）、（PubMed）、（Science Citation Index Expanded）与（Scopus）收录。